What Peter Attia's 'Outlive' gets right about blood testing

Peter Attia's Outlive: The Science and Art of Longevity argues that modern medicine is reactive by design. It waits for disease to arrive, then treats it. He calls the alternative Medicine 3.0: proactive, preventive, personalised, and built on continuous measurement rather than episodic screening.

The framework resonated because it named something millions of people already felt. The standard medical model wasn't built for someone who is well but wants to stay well. It was built for someone who is sick and needs treatment. The gap between those two purposes is where Attia's entire thesis lives.

VitalYOU's clinical model occupies the same gap. The alignment is structural, not branding. Both start from the premise that the most valuable time to assess biology is before something goes wrong. Both use blood-based measurement as the foundation. And both argue that standard reference ranges, which capture the middle 95% of a population that includes significant numbers of unwell people, are insufficient for assessing performance.

The question worth asking is specific: which markers does Attia advocate, and how do they map to what VitalYOU actually tests?

Metabolic health: Attia's central thesis

Attia's strongest clinical argument centres on metabolic dysfunction. He positions insulin resistance as the upstream driver of cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. His framework doesn't wait for a fasting glucose of 7 or an HbA1c of 6.5 to intervene. It intervenes at the earliest detectable signal.

The markers he advocates:

Fasting insulin is Attia's primary metabolic marker. He's argued repeatedly that fasting insulin is a more sensitive early indicator of metabolic dysfunction than fasting glucose, which can remain normal for years while the pancreas works progressively harder to maintain it. By the time glucose rises, insulin resistance has been developing for a decade.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated from fasting glucose and fasting insulin. It's the gold standard fasting measure of insulin sensitivity. Standard GP panels in Australia include fasting glucose. They rarely include fasting insulin, which means HOMA-IR can't be calculated.

HbA1c (glycated haemoglobin) reflects average blood glucose over approximately three months. Attia treats it as a tracking marker, not a diagnostic one. An HbA1c of 5.4% is well below the diabetic threshold (6.5%) but above the range Attia considers optimal (below 5.1%). VitalYOU's optimal ceiling matches this at 5.1%.

Triglycerides and the triglyceride:HDL ratio are Attia's preferred markers for metabolic health beyond insulin. The trig:HDL ratio is one of the best single-number proxies for insulin resistance: a ratio below 1.0 (in mmol/L) indicates metabolically healthy physiology.

VitalYOU's metabolic panel includes all of these. Fasting insulin, HOMA-IR, triglyceride:HDL ratio, and triglycerides are classified as functional markers in the metabolic system (S2). HbA1c and fasting glucose are tracking markers. The classification mirrors Attia's hierarchy: functional markers tell you what's happening now, tracking markers tell you which direction things are moving.

Cardiovascular risk: ApoB and beyond

Attia has been one of the most vocal advocates for ApoB as the primary cardiovascular risk marker, arguing that LDL cholesterol is an imprecise proxy for the particle count that actually drives atherosclerotic plaque formation.

ApoB measures the number of atherogenic lipoprotein particles in circulation. Each LDL particle, each VLDL remnant, and each IDL particle carries one ApoB molecule. The count is a more direct measure of cardiovascular risk than LDL-C because it captures the total atherogenic particle burden, including the small dense LDL particles that LDL-C can undercount.

Lp(a) (lipoprotein(a)) is genetically determined and currently has no approved pharmaceutical intervention to lower it. Attia advocates measuring it once as a risk stratification tool. If elevated (above approximately 75 nmol/L), it significantly increases cardiovascular risk independent of LDL and ApoB.

VitalYOU's panel includes both ApoB (classified as a risk marker in S2) and Lp(a). Standard GP lipid panels typically include total cholesterol, LDL, HDL, and triglycerides. They don't include ApoB or Lp(a). For someone following Attia's framework, the standard panel provides an incomplete cardiovascular risk picture.

Hormonal assessment

Outlive addresses hormonal health primarily in the context of ageing: testosterone decline in men, oestrogen and progesterone decline in women, thyroid function, and the reciprocal relationships between hormones, sleep, and metabolic health. Attia's position is that hormonal assessment should be part of routine monitoring in midlife, not something reserved for symptomatic patients.

VitalYOU's hormonal panel (S1) includes free testosterone, total testosterone, SHBG, oestradiol, progesterone, DHEA-S, free T3, free T4, TSH, FSH, LH, cortisol, and prolactin. This covers the full hormonal picture that Attia's framework implies but doesn't always specify marker by marker.

The cross-system interpretation is where VitalYOU adds something Attia's framework describes conceptually but doesn't operationalise in Outlive. Testosterone doesn't exist independently of cortisol (which suppresses it under chronic stress), thyroid function (which modulates metabolic rate and energy), or insulin sensitivity (insulin resistance promotes aromatisation of testosterone to oestrogen). VitalYOU's Marker Hierarchy defines which markers are functional, which are tracking, and how conflicts between them should be resolved.

Inflammation

Attia advocates for hs-CRP as a standard inflammatory marker and has discussed the role of chronic low-grade inflammation as a driver across all four of what he calls the "horsemen" (cardiovascular disease, cancer, neurodegeneration, and metabolic disease).

VitalYOU's inflammatory panel (S4) includes hs-CRP (functional), uric acid (functional), ferritin (tracking, interpreted directionally), and homocysteine (which bridges inflammatory and neurotransmitter systems). The inclusion of homocysteine goes beyond what Attia typically emphasises but aligns with the research linking elevated homocysteine to both cardiovascular risk and cognitive decline.

Where VitalYOU goes further

Outlive is a framework. VitalYOU is a clinical service. The distinction matters because a framework tells you what to think about. A clinical service measures, interprets, and acts.

Three areas where VitalYOU's panel extends beyond what Outlive specifies:

Cognitive and Neurological Cofactor. VitalYOU's S6 system includes iron (functional, as a dopamine synthesis cofactor), vitamin B12 (functional, for myelin and neurotransmitter synthesis), vitamin D (tracking, as a neurosteroid precursor), and magnesium (tracking, for NMDA receptor modulation). Attia discusses brain health primarily through the lens of cardiovascular and metabolic risk to the brain. VitalYOU adds a layer that assesses the cofactors the brain needs to function day-to-day, not just the risk factors that threaten it long-term.

Systemic Stress and Recovery. Attia devotes significant attention to sleep in Outlive but primarily from a behavioural and sleep hygiene perspective. While peripheral blood cannot directly quantify "sleep," VitalYOU evaluates physiological stress and recovery via IGF-1 (functional, reflecting overnight growth hormone pulsatility and restorative capacity) alongside cortisol and magnesium. This provides a blood-based window into systemic recovery that wearables and questionnaires can't fully capture.

Cross-system interpretation. Outlive describes how metabolic, cardiovascular, and hormonal systems interact. VitalYOU's Marker Hierarchy operationalises this with specific conflict resolution rules. When metabolic functional markers are optimal but tracking markers flag marginally, the narrative doesn't overcall pathology. When symptom signals are strong but metabolic markers are clean, they are attributed to their root source rather than assumed metabolic. These rules prevent the pattern that Outlive warns against: treating each marker in isolation when the clinical value is in how they interact.

What this article is and isn't

Attia discusses specific interventions in Outlive, including prescription medications used off-label for longevity purposes. VitalYOU does not comment on specific pharmaceutical interventions in its public content. The clinical value of Attia's framework for VitalYOU's audience is in the diagnostic philosophy, not the treatment layer. Measure proactively. Interpret against optimal, not just normal. Track over time. Act on the pattern, not the individual number.

If you've read Outlive and found yourself thinking "I need to actually do this," the next step is straightforward. The markers Attia advocates are the markers VitalYOU tests. The framework he describes is the framework VitalYOU's doctors use. The gap between reading about Medicine 3.0 and living it is a blood draw and a consultation.

The best time to measure your biology is before you need to.